News for PMV Pharmaceuticals, Inc. (PMVP)

PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (”œPMV Pharma”; PMVP), a precision oncology company pioneering the discovery a

**media[635670]**

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type ad

As of the end of the first quarter, PMV Pharmaceuticals (PMVP) reported holding $165.8 million in cash, cash equivalents, and marketable securities. This marks

PMV Pharmaceuticals (PMVP) reports a net loss of $17.5 million for Q1 2025, an increase from $15.3 million in Q1 2024. Cash and equivalents stand at $16

**media[620336]**

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type ad

Significant Transaction by PFM Health Sciences, LP (Trades, Portfolio) On February 13, 2025, PFM Health Sciences, LP (Trades, Portfolio) executed a notable tran

PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type...

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type...

PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today...

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and...

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian...

Financial Position: PMV Pharmaceuticals ended 2023 with $228.6 million in cash, cash equivalents, and marketable securities.Net Loss: Reported a net loss of $6